Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.

Item
http://www.wikidata.org/entity/Q40355993
NK cell-based immunotherapy for malignant diseases.Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
P2860

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.

Item
http://www.wikidata.org/entity/Q40355993
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immunotherapy in high-risk che ...... d with rIL-2: a phase I study.
@en
type
label
Immunotherapy in high-risk che ...... d with rIL-2: a phase I study.
@en
prefLabel
Immunotherapy in high-risk che ...... d with rIL-2: a phase I study.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P356
P1433
P1476
Immunotherapy in high-risk che ...... d with rIL-2: a phase I study.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698